{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:59:48Z","timestamp":1790780388749,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["DEC-2013\/09\/N\/NZ4\/02045"],"award-info":[{"award-number":["DEC-2013\/09\/N\/NZ4\/02045"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre","doi-asserted-by":"publisher","award":["DEC-2016\/20\/T\/NZ3\/00504"],"award-info":[{"award-number":["DEC-2016\/20\/T\/NZ3\/00504"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.neuropharm.2018.02.023","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T12:28:15Z","timestamp":1519388895000},"page":"139-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4170-9732","authenticated-orcid":false,"given":"Joanna","family":"Motyl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Przykaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142 M.","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna B.","family":"Strosznajder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.02.023_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-017-0913-3","article-title":"Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East","volume":"17","author":"Achiron","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib2","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnana.2014.00155","article-title":"Parkinson's disease: animal models and dopaminergic cell vulnerability","volume":"8","author":"Blesa","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuro.2013.03.005","article-title":"Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL\/6J mice","volume":"37","author":"Breckenridge","year":"2013","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib5","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070124","article-title":"FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke","volume":"8","author":"Brunkhorst","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fncel.2014.00283","article-title":"Fingolimod for the treatment of neurological diseases-state of play and future perspectives","volume":"8","author":"Brunkhorst","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2051-5960-2-12","article-title":"Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease","volume":"2","author":"Ceccom","year":"2014","journal-title":"Acta Neuropathol. Commun"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bbr.2011.11.019","article-title":"Partial dopamine depletion in MPTP-treated mice differentially altered motor skill learning and action control","volume":"228","author":"Chagniel","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.neuroscience.2006.04.022","article-title":"Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice","volume":"141","author":"Chalimoniuk","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10571-006-9078-0","article-title":"Phosphatidylinositol transfer protein expression altered by aging and Parkinson disease","volume":"26","author":"Chalimoniuk","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bbalip.2012.07.005","article-title":"Post-translational regulation of sphingosine kinases","volume":"1831","author":"Chan","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib92","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12031-013-0030-8","article-title":"Pramipexole reduces phosphorylation of alpha-synuclein at serine-129","volume":"51","author":"Chau","year":"2013","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0304-3940(96)13091-3","article-title":"Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 5,7-dihydroxytryptamine on the locomotor activity and striatal amines in C57BL\/6 mice","volume":"218","author":"Chia","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137193","article-title":"The molecular mechanism of amyloid \u03b242 peptide toxicity: the role of sphingosine kinase-1 and mitochondrial sirtuins","volume":"10","author":"Cie\u015blik","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.biochem.74.082803.133400","article-title":"The biochemistry of Parkinson's disease","volume":"74","author":"Cookson","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2051-5960-2-9","article-title":"Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis","volume":"2","author":"Couttas","year":"2014","journal-title":"Acta Neuropathol. Commun"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib19","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s12035-014-8807-5","article-title":"Sphingosine-1-Phosphate and its effect on glucose deprivation\/glucose reload stress: from gene expression to neuronal survival","volume":"51","author":"Czubowicz","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12035-013-8606-4","article-title":"Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate","volume":"50","author":"Czubowicz","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib21","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1073\/pnas.1206093109","article-title":"Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome","volume":"109","author":"Deogracias","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib22","doi-asserted-by":"crossref","first-page":"15833","DOI":"10.1074\/jbc.M609124200","article-title":"Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues","volume":"282","author":"Don","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2210-10-2","article-title":"Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole","volume":"10","author":"Ferrari-Toninelli","year":"2010","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02260967","article-title":"MPTP-induced behavioural and biochemical deficits: a parametric analysis","volume":"7","author":"Fredriksson","year":"1994","journal-title":"J.\u00a0Neural Transm. Park. Dis. Dement. Sect"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/DDDT.S130514","article-title":"Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease","volume":"11","author":"Ganguly","year":"2017","journal-title":"Drug Des. Devel. Ther"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11064-014-1240-3","article-title":"Sphingosine kinases\/sphingosine-1-phosphate and death signalling in APP-transfected cells","volume":"39","author":"Gassowska","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12703\/P6-109","article-title":"S1P signaling: new therapies and opportunities","volume":"6","author":"Gonzalez-Cabrera","year":"2014","journal-title":"F1000Prime Rep"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nn.3728","article-title":"Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory","volume":"17","author":"Hait","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1471-4159.1985.tb07120.x","article-title":"Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse","volume":"44","author":"Hallman","year":"1985","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib31","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12975-013-0260-7","article-title":"Role of the sphingosine metabolism pathway on neurons against experimental cerebral ischemia in rats","volume":"4","author":"Hasegawa","year":"2013","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1161\/STROKEAHA.109.568899","article-title":"Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats","volume":"41","author":"Hasegawa","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","article-title":"Deregulation of sphingolipid metabolism in Alzheimer's disease","volume":"31","author":"He","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0006-8993(80)90871-9","article-title":"Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization","volume":"195","author":"Hefti","year":"1980","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib35","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1126\/science.6610213","article-title":"Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice","volume":"224","author":"Heikkila","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib36","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbr.2013.06.016","article-title":"Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with Memantine","volume":"252","author":"Hemmati","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2018.02.023_bib37","doi-asserted-by":"crossref","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","article-title":"Neuroinflammation in Parkinson's disease","volume":"18","author":"Hirsch","year":"2012","journal-title":"Parkinsonism Relat. Disord"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib38","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1126\/science.1065323","article-title":"Lysophospholipids\u2013receptor revelations","volume":"294","author":"Hla","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The direct effects of fingolimod in the central nervous system: implications for relapsing multiple sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugse"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neulet.2008.05.067","article-title":"Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity","volume":"440","author":"Imamura","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2018.02.023_bib41","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/S1353-8020(11)70057-8","article-title":"Animal models of Parkinson's disease","volume":"18","author":"Jackson-Lewis","year":"2012","journal-title":"Parkinsonism Relat. Disord"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jnr.20114","article-title":"Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway","volume":"76","author":"Jakowec","year":"2004","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1741-7007-2-22","article-title":"Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor","volume":"2","author":"Joyce","year":"2004","journal-title":"BMC Biol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib44","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1161\/STROKEAHA.113.002880","article-title":"FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-infammation but not by direct neuroprotection","volume":"44","author":"Kraft","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib45","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F","article-title":"Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-phenyl-1,2,3,6-tetrahydrophyridine exposure","volume":"46","author":"Langston","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib46","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s007020070030","article-title":"Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection","volume":"107","author":"Le","year":"2000","journal-title":"J.\u00a0Neural. Transm."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib47","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1007\/s11064-010-0214-3","article-title":"Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease","volume":"35","author":"Li","year":"2010","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib48","doi-asserted-by":"crossref","first-page":"37118","DOI":"10.1074\/jbc.M502207200","article-title":"SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism","volume":"280","author":"Maceyka","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib49","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib50","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1124\/mol.60.6.1325","article-title":"14-3-3 inhibits Bad-induced cell death through interaction with serine-136","volume":"60","author":"Masters","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12035-016-0317-1","article-title":"Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders","volume":"55","author":"Motyl","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1096\/fj.12-219618","article-title":"Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network","volume":"27","author":"Nagahashi","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib52","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1111\/febs.12314","article-title":"Roles, regulation and inhibitors of sphingosine kinase 2","volume":"280","author":"Neubauer","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2012.12.005","article-title":"Fingolimod phosphate promotes the neuroprotective effects of microglia","volume":"256","author":"Noda","year":"2013","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuropharm.2016.11.006","article-title":"Sphingosine-1-phosphate receptor therapies: advances in clinical trials for CNS-related diseases","volume":"113","author":"O'Sullivan","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-phosphate receptor modulators and drug discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol. Ther"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0014-5793(03)01168-2","article-title":"The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2","volume":"554","author":"Paugh","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib58","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF03033178","article-title":"Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists","volume":"5","author":"Presgraves","year":"2003","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.expneurol.2004.06.021","article-title":"Involvement of dopamine D 2\/D 3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells","volume":"190","author":"Presgraves","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrn.2017.25","article-title":"The two-century journey of Parkinson disease research","volume":"18","author":"Przedborski","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib61","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/10409238.2015.1039115","article-title":"Sphingosine-1-phosphate metabolism: a structural perspective","volume":"50","author":"Pulkoski-Gross","year":"2015","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbior.2015.09.001","article-title":"Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation","volume":"60","author":"Pyne","year":"2016","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.plipres.2016.03.001","article-title":"Sphingosine 1-phosphate and sphingosine kinases in health and disease: recent advances","volume":"62","author":"Pyne","year":"2016","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib64","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5114\/fn.2014.45567","article-title":"The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinson's disease","volume":"52","author":"Pyszko","year":"2014","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12035-013-8622-4","article-title":"Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells","volume":"50","author":"Pyszko","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib66","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/archneurol.2012.1051","article-title":"Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiplesclerosis","volume":"69","author":"Radue","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib67","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s11064-016-2125-4","article-title":"FTY720 attenuates 6-OHDA-associated dopaminergic degeneration in cellular and mouse parkinsonian models","volume":"42","author":"Ren","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-8993(86)90905-4","article-title":"Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment","volume":"376","author":"Ricaurte","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib69","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jcb.20127","article-title":"Structural and functional characteristics of S1P receptors","volume":"92","author":"Sanchez","year":"2004","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0166-4328(01)00309-6","article-title":"Behavioral phenotyping of the MPTP mouse model of Parkinson's disease","volume":"125","author":"Sedelis","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib71","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.neuroscience.2015.01.032","article-title":"Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson's disease and in MPP+ -treated MN9D cells in\u00a0vitro","volume":"290","author":"Sivasubramanian","year":"2015","journal-title":"Neurosci"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","article-title":"Glutathione metabolism and Parkinson's disease","volume":"62","author":"Smeyne","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib72","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrm1103","article-title":"Sphingosine-1-phosphate: an enigmatic signalling lipid","volume":"4","author":"Spiegel","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3727\/000000007783464704","article-title":"Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys","volume":"16","author":"Stephenson","year":"2007","journal-title":"Cell Transplant."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib74","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/WNL.35.10.1506","article-title":"Intellectual changes in patients with MPTP-induced parkinsonism","volume":"35","author":"Stern","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib75","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/STROKEAHA.115.012236","article-title":"Selective sphingosine-1-phosphate receptor 1 modulation attenuates experimental intracerebral hemorrhage","volume":"47","author":"Sun","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib76","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/0024-3205(87)90588-1","article-title":"Behavioral and biochemical changes following acute administration of MPTP and MPP+","volume":"40","author":"Tadano","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/pr.107.07113","article-title":"\u201cInside-out\u201d signaling of sphingosine-1-phosphate: therapeutic targets","volume":"60","author":"Takabe","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib78","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1523\/JNEUROSCI.6467-10.2011","article-title":"BACE1 activity is modulated by cell-associated sphingosine-1-phosphate","volume":"31","author":"Takasugi","year":"2011","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib79","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2009.09.055","article-title":"Akt signal transduction dysfunction in Parkinson's disease","volume":"467","author":"Timmons","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib80","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cbpb.2012.05.006","article-title":"The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell survival and death","volume":"163","author":"Van Brocklyn","year":"2012","journal-title":"Comp. Biochem. Physiol. B Biochem. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib81","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s11064-014-1290-6","article-title":"Sphingosine kinase-1 protects differentiated N2a cells against beta-amyloid25-35-induced neurotoxicity via the mitochondrial pathway","volume":"39","author":"Yang","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cen3.12397","article-title":"Neurological safety of fingolimod: an updated review","volume":"8","author":"Yoshii","year":"2017","journal-title":"Clin. Exp. Neuroimmunol"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib83","first-page":"9450137","article-title":"Neuroprotective effects of salidroside in the MPTP mouse model of Parkinson's disease: involvement of the PI3K\/Akt\/GSK3\u03b2 pathway","volume":"2016","author":"Zhang","year":"2016","journal-title":"Parkinsons. Dis"},{"key":"10.1016\/j.neuropharm.2018.02.023_bib84","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11596-013-1136-5","article-title":"Effects of small interfering RNA targeting sphingosine kinase-1 gene on the animal model of Alzheimer's disease","volume":"33","author":"Zhang","year":"2013","journal-title":"J.\u00a0Huazhong Univ. Sci. Technol. - Med. Sci."},{"key":"10.1016\/j.neuropharm.2018.02.023_bib85","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1096\/fj.201600751R","article-title":"Neuroprotective effects of fingolimod in mouse models of Parkinsons disease","volume":"31","author":"Zhao","year":"2017","journal-title":"FASEB J."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T12:42:09Z","timestamp":1603888929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818300893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":86,"alternative-id":["S0028390818300893"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.023","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson's disease by activation of sphingosine kinase 1 and Akt kinase","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}